The use of artificial intelligence-aided drug discovery platforms and big data analytics for investigating correlations between aberrant DDX41 expression and DDX41-induced pathological conditions may facilitate the development of therapeutic options for patients with hematological malignancies caused by overexpression or dysfunction of DDX41. The gene discussed is DDX41; the disease is hematologic disorder.